Powerful cocktail shows promise against bone marrow cancer
NCT ID NCT02969837
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study tested a combination of four drugs (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) in 46 people newly diagnosed with multiple myeloma, a blood cancer. The goal was to see how many patients achieved a very deep remission (stringent complete response or minimal residual disease negativity). The treatment showed strong effectiveness, but multiple myeloma typically requires ongoing management, so this is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NorthShore University Health System
Evanston, Illinois, 60201, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.